We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2–selective agonist, in patients with narcolepsy type 1. Patients with confirmed narcolepsy type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results